Sort
82,697 grants matching “vaccine development”
Mechanisms Of Immune Mediated Restriction Of HIV Replication In LTNP
$999,369Mark Connors · National Institute Of Allergy And Infectious Diseases · ZIA · FY2018 · AI
Progressing PfSPZ vaccines for malaria to licensure and commercialization
$999,345Stephen Lev Hoffman · Sanaria, Inc. · SB1 · FY2024 · AI
Advancing a Mucosal HSV-2 Vaccine Towards Clinical Trials
$999,334Kejian Yang · Biomedical Research Models, Inc. · R44 · FY2015 · AI
i-AKC: Integrated AIRR Knowledge Commons
$999,330Lindsay G. Cowell · Ut Southwestern Medical Center · U24 · FY2023 · AI
Vaccine Development for Oral Carcinoma
$999,323University Of Pittsburgh At Pittsburgh · P01 · FY2005 · DE
Genomic Studies of the Impact of External Factors on Parasite Development and Disease Outcome
$999,314Joana Carneiro Da Silva · University Of Maryland Baltimore · U19 · FY2020 · AI
A glycolipid adjuvant to promote dose sparing, accelerate immunization schedules and extend durability of high-level protection with an attenuated, live sporozoite malaria vaccine
$999,306Stephen Lev Hoffman · Sanaria, Inc. · R44 · FY2022 · AI
Integrin activator-adjuvanted DNA vaccine against Trypanosoma cruzi infection
$999,300Upendra Marathi · 7 Hills Pharma, Llc · R44 · FY2022 · AI
Novel G protein-based RSV vaccine
$999,290Shengqiang Li · Sciogen, Llc · R44 · FY2023 · AI
Final Preclinical Testing and Formulation of a Scalable, Live-attenuated SARS-CoV-2 Vaccine
$999,267Steffen Mueller · Codagenix, Inc. · R44 · FY2021 · AI
Development of 4-(aroylamino)piperidine-based entry inhibitors as anti-influenza therapeutics
$999,234Lijun Rong · Chicago Biosolutions, Inc. · R42 · FY2024 · AI
Strain-Independent Therapeutic Antibodies for Influenza
$999,214Lawrence Michael Kauvar · Trellis Bioscience, Inc. · R44 · FY2020 · AI
Development of Coccidioides Cytokine Release Assay
$999,212Eric Holbrook · Miravista Diagnostics, Llc · R44 · FY2023 · AI
The ExCITE Program: Expediting Commercialization, Innovation, Translation, & Entrepreneurship
$999,194Paula J Bates · University Of Louisville · U01 · FY2015 · HL
The ExCITE Program: Expediting Commercialization, Innovation, Translation, & Entrepreneurship
$999,194Paula J Bates · University Of Louisville · U01 · FY2016 · HL
A genetically modified Plasmodium falciparum sporozoite vaccine attenuated at the late-liver stage
$999,150B. Kim Lee Sim · Sanaria, Inc. · R44 · FY2025 · AI
In vivo dose finding for IN-002 in neonatal lambs for inhaled immunotherapy of RSV
$999,032Richard A Cone · Mucommune, Llc · R44 · FY2020 · AI
Manufacture of aseptic, purified, cryopreserved Plasmodium vivax sporozoites
$999,025Stephen Lev Hoffman · Sanaria, Inc. · R44 · FY2020 · AI
A genetically modified Plasmodium falciparum sporozoite vaccine attenuated at the late-liver stage
$998,971B. Kim Lee Sim · Sanaria, Inc. · R44 · FY2024 · AI
#4Corners4Health: A Social Media Cancer Prevention Program for Rural Emerging Adults
$998,970David B Buller · Klein Buendel, Inc. · R01 · FY2024 · CA
Development of a Vaccine for HIV-AIDS: Cellular Immunity
$998,897Marjorie Robert-Guroff · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA
Universal Influenza A/B Vaccine
$998,889Kenneth C Bagley · Orlance, Inc. · R44 · FY2023 · AI
NIAID Preclinical Development Support - Development of clade C Vaccine
$998,870Phillip Ishikawa · Advanced Bioscience Laboratories, Inc. · N01 · FY2015 · AI
PfSPZ Vaccine for Malaria: Towards a Successful Biologics License Application and Commercialization
$998,833Stephen Lev Hoffman · Sanaria, Inc. · SB1 · FY2020 · AI
Development of highly potent human monoclonal for RSV immuno-prophylaxis
$998,825Larry Zeitlin · Mapp Biopharmaceutical, Inc. · R44 · FY2020 · AI